Prior radiotherapy within  weeks of initiating treatment; Must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
Prior surgery or radiotherapy within  days of initiating study drug(s). Patients must have recovered from all radiation-related toxicities, not required corticosteroids and have not had radiation pneumonitis.
Prior surgery or radiotherapy within  days of initiating therapy. Patients must have recovered from all radiation-related toxicities, and not required corticosteroids.
Has recovered from all radiation-related toxicities, does not require corticosteroids, and has not had radiation pneumonitis
Has received prior radiotherapy within  weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A -week washout is permitted for palliative radiation (=<  weeks of radiotherapy) to non-central nervous system (CNS) disease
Prior radiotherapy or gamma knife within  weeks of study treatment for non-brain metastasis; subjects must have recovered from all radiation related toxicities
Prior radiotherapy or gamma knife within  weeks of study treatment for non-brain metastasis; subjects must have recovered from all radiation related toxicities
Received prior radiotherapy within  weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A -week washout is permitted for palliative radiation (? weeks of radiotherapy) to non-central nervous system (CNS) disease.
REGISTRATION TO TREATMENT (STEP ): Patient must not have had prior chemotherapy, targeted small molecule therapy (aside from imatinib, dasatinib, or nilotinib), or radiation therapy within  weeks prior to study registration; patients also must have recovered from all adverse events due to a previously administered agent\r\n* Note: Patients with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis; a -week washout is permitted for palliative radiation (=<  weeks of radiotherapy) to non-central nervous system [CNS] disease)
REGISTRATION TO TREATMENT (STEP ): Patient must not have had prior chemotherapy, targeted small molecule therapy (aside from imatinib, dasatinib, or nilotinib), or radiation therapy within  weeks prior to study registration; patients also must have recovered from all adverse events due to a previously administered agent\r\n* NOTE: Patients with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis; a -week washout is permitted for palliative radiation (=<  weeks of radiotherapy) to non-CNS disease
DOSE ESCALATION COHORT: Subjects who have had prior radiotherapy within  weeks of therapy; subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
DOSE EXPANSION COHORT: Subjects who have had prior radiotherapy within  weeks of therapy; subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
Has received prior radiotherapy within  weeks of start of study treatment; participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis; a -week washout is permitted for palliative radiation (=<  weeks of radiotherapy) to non-central nervous system (CNS) disease
Have undergone chest irradiation within  weeks prior to study drug administration, have not recovered from all radiation-related toxicities, or requires corticosteroids. A -week washout is permitted for focal palliative radiation to non-central nervous system disease.
Prior radiotherapy within  weeks of therapy; Must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.